Clinical study report

1) Name of Sponsor/Company:

- Investigator-initiated-trial with co-financing by Bayer AG

2) Name of Finished Product:

- Ventavis® (Drug code Q4074; ATC code: B01AC11)

3) Name of Active Substance:

- Iloprost

4) Individual Study Table:

- not applicable

5) Title of Study

- Iloprost for bridging to heart transplantation in patients with pulmonary hypertension and left heart failure – BRIDGE (Version 1.3, 14.04.2014)

6) Intended Investigators:

- Prof. Dr. Ekkehard Grünig (early termination prior to recruitment)

7) Intended Study centre(s):

- Thoraxclinic at Heidelberg University, Heidelberg, Germany; Herzzentrum Bad Oeynhausen

8) Publication (reference):

- not applicable

9) Studied period (years):

- BfArm approval was given on April 2nd 2014. The study was terminated early due to delay in study initiation the 29th of January 2015 by the medical company Bayer. The study was stopped before recruitment and enrolment of patients into the study.

10) Phase of development:

- IIA (proof of concept)

11) Objectives:

Primary [Objectives/ Endpoints]

- The primary objective of the clinical trial was to get first data on safety and tolerability of treatment with inhaled Iloprost in patients with left heart failure who are listed for orthotopic heart transplantation.

Secondary [Objectives/ Endpoints]

- Secondary objectives were to preserve quality of life and to prevent worsening of any other organ functions induced by LHF and PH as determined by clinical laboratory values [NTproBNP], medical symptoms, ECG, echocardiography, cardiopulmonary exercise testing, quality of life, concomitant diseases and medications.

- Hemodynamic parameters determined by RHC as PVR, cardiac output, PAP, PCWP, RA-pressure

- Echocardiography

- Spiroergometry

- Quality of Life (QoL): SF-36, CAMPHOR

- Need for rescue medication (Bosentan)

- Safety parameters

- Hemodynamics would have been evaluated at V2 and V6, the other parameters at V1, V2, V3, V4, V5, and V6 or at any day of premature treatment termination

12) Methodology:

- Randomised, controlled, double-blind, trial of 12-week Iloprost treatment in patients with pulmonary hypertension and left heart disease as bridging to transplantation. This exploratory proof-of-concept trial was planned to obtain first data on safety and tolerability in this patient population.

13) Number of patients (planned and analysed):

- 40 planned, 0 analysed

14) Diagnosis and main criteria for inclusion:

- Female and male patients of any ethnic origin with left heart insufficiency and secondary PH

- Having fulfilled his/her 18th birthday on Visit 1 (Day -7 to -1) of the study

- Written informed consent

- Modified WHO functional class III-IV

- PH diagnosed by right heart catheter showing:

    - Baseline mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg
    - Baseline pulmonary vascular resistance (PVR) > 230 dyn x s x cm-5
    - Baseline transpulmonary gradient (TPG) > 15 mm Hg

15) Test product, dose and mode of administration, batch number:

- 2 inhalations per day of 2.5 µg Iloprost [Ventavis®] per inhalation to a maximum of 6 inhalations per day of 5 µg Iloprost per inhalation (total daily dose 5 - 30 µg)

16) Duration of treatment:

- planned treatment duration of 85±2 days

17) Reference therapy, dose and mode of administration, batch number:

- placebo solution

18) Criteria for evaluation:

- not applicable

19) Statistical methods:

- not applicable

20) Summary – Conclusions:

- not applicable

21) Date of report:

- August 13th 2021